IBDEI1L1 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28086,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,28087,0)
 ;;=289.0^^162^1791^53
 ;;^UTILITY(U,$J,358.3,28087,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28087,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,28087,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,28087,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,28088,0)
 ;;=238.4^^162^1791^107
 ;;^UTILITY(U,$J,358.3,28088,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28088,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,28088,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,28088,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,28089,0)
 ;;=V58.61^^162^1791^123
 ;;^UTILITY(U,$J,358.3,28089,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28089,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,28089,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,28089,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,28090,0)
 ;;=282.49^^162^1791^115
 ;;^UTILITY(U,$J,358.3,28090,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28090,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,28090,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,28090,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,28091,0)
 ;;=289.89^^162^1791^14
 ;;^UTILITY(U,$J,358.3,28091,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28091,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,28091,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,28091,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,28092,0)
 ;;=238.79^^162^1791^86
 ;;^UTILITY(U,$J,358.3,28092,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28092,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,28092,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis NEC
 ;;^UTILITY(U,$J,358.3,28092,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,28093,0)
 ;;=287.30^^162^1791^108
 ;;^UTILITY(U,$J,358.3,28093,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28093,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,28093,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,28093,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,28094,0)
 ;;=288.09^^162^1791^7
 ;;^UTILITY(U,$J,358.3,28094,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28094,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,28094,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,28094,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,28095,0)
 ;;=284.81^^162^1791^13
 ;;^UTILITY(U,$J,358.3,28095,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28095,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,28095,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,28095,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,28096,0)
 ;;=284.89^^162^1791^12
 ;;^UTILITY(U,$J,358.3,28096,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28096,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,28096,1,5,0)
 ;;=5^Aplastic Anemia d/t Chr disease
 ;;^UTILITY(U,$J,358.3,28096,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,28097,0)
 ;;=289.84^^162^1791^116
 ;;^UTILITY(U,$J,358.3,28097,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28097,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,28097,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,28097,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,28098,0)
 ;;=204.02^^162^1791^2
 ;;^UTILITY(U,$J,358.3,28098,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28098,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,28098,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,28098,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,28099,0)
 ;;=204.12^^162^1791^48
 ;;^UTILITY(U,$J,358.3,28099,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28099,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,28099,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,28099,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,28100,0)
 ;;=204.21^^162^1791^113
 ;;
 ;;$END ROU IBDEI1L1
